LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lantern Pharma Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.64−0.03 (-4.05%)
Close on Oct 19, 2026
- Market cap
- $7.97M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -57.2% | -123.5% | |
| Return on assets | – | -54.2% | -93.5% | |
| Current ratio | – | 36.64 | 2.40 | |
| Diluted shares | – | 4M | 11M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Lantern Pharma generated $71.20M from operations and spent $4.00M on capital expenditure, dividends and share buybacks. 2% of that went back into the business.
Generated
$71.20M
Used
$4.00M
Capital expenditure$76.39K2%Dividends$00%Share buybacks$3.92M98%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$17.12M
- Cash generatingOperating cash flow above zero-$15.68M
- Return on assets improvedROA up on the prior year-47.6% → -66.9%
- Earnings backed by cashOperating cash flow above net income-$15.68M vs -$17.12M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.83 → 2.40
- No dilutionShare count did not rise11M → 11M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –